ANAPTYSBIO, INC. Interest Income, Other
ANAPTYSBIO, INC. (ANAB) reported Interest Income, Other of $3.25 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-09-21
- ANAPTYSBIO, INC. interest income, other for the quarter ending 2026-06-30 was $599.00K, a 83.61% decline year-over-year.
- ANAPTYSBIO, INC. interest income, other for the quarter ending 2026-03-31 was $2.65M, a 39.88% decline year-over-year.
- ANAPTYSBIO, INC. interest income, other for the quarter ending 2025-12-31 was -$1.18M, a 316.94% decline year-over-year.
- ANAPTYSBIO, INC. interest income, other for the quarter ending 2025-09-30 was $2.92M, a 45.08% decline year-over-year.
- ANAPTYSBIO, INC. interest income, other for fiscal 2025 was $9.81M, a 34.90% decline from fiscal 2024.
- ANAPTYSBIO, INC. interest income, other for fiscal 2024 was $15.07M, a 20.13% decline from fiscal 2023.
- ANAPTYSBIO, INC. interest income, other for fiscal 2023 was $18.87M, a 149.97% increase from fiscal 2022.
- ANAPTYSBIO, INC. interest income, other for fiscal 2022 was $7.55M, a 1651.74% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 6 month as first filed | Interest Income, Other 9 month | Interest Income, Other 12 month | Interest Income, Other 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $599.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $3.25M 10-KT · filed 2026-09-21 | $2.07M derived: sum of 3 quarters · filed 2026-09-21 | $5.00M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-12 | $1.48M derived: sum of 2 quarters · filed 2026-09-21 | $4.40M derived: sum of 3 quarters · filed 2026-09-21 | $8.05M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | -$1.18M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $1.75M derived: sum of 2 quarters · filed 2026-09-21 | $5.40M derived: sum of 3 quarters · filed 2026-09-21 | $9.81M 10-KT · filed 2026-09-21 | $13.50M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $2.92M 10-Q · filed 2025-11-04 | $6.58M derived: sum of 2 quarters · filed 2025-11-04 | $10.99M 10-Q · filed 2025-11-04 | $11.53M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | $3.65M 10-Q · filed 2025-08-06 | $5.40M 10-KT · filed 2026-09-21 | $8.07M 10-Q · filed 2025-08-06 | $8.61M derived: sum of 3 quarters · filed 2026-09-21 | $13.93M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2025-03-31 | $4.41M 10-Q · filed 2026-05-12 | $4.96M derived: sum of 2 quarters · filed 2026-09-21 | $10.28M derived: sum of 3 quarters · filed 2026-09-21 | $14.90M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2024-12-31 | $543.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $5.87M derived: sum of 2 quarters · filed 2026-09-21 | $10.49M derived: sum of 3 quarters · filed 2026-09-21 | $15.07M 10-KT · filed 2026-09-21 | $19.79M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $5.32M 10-Q · filed 2025-11-04 | $9.95M derived: sum of 2 quarters · filed 2025-11-04 | $14.53M 10-Q · filed 2025-11-04 | $19.41M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $4.62M 10-Q · filed 2025-08-06 | $9.21M 10-Q · filed 2025-08-06 | $14.09M derived: sum of 3 quarters · filed 2026-03-03 | $18.94M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $4.58M 10-Q · filed 2025-05-05 | $9.46M derived: sum of 2 quarters · filed 2026-03-03 | $14.32M derived: sum of 3 quarters · filed 2026-03-03 | $18.97M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $9.73M derived: sum of 2 quarters · filed 2026-03-03 | $14.39M derived: sum of 3 quarters · filed 2026-03-03 | $18.87M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $4.85M 10-Q · filed 2024-11-05 | $9.51M derived: sum of 2 quarters · filed 2024-11-05 | $13.99M 10-Q · filed 2024-11-05 | $17.83M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $4.65M 10-Q · filed 2024-08-05 | $9.14M 10-Q · filed 2024-08-05 | $12.98M derived: sum of 3 quarters · filed 2025-02-27 | $15.24M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $4.49M 10-Q · filed 2024-05-09 | $8.32M derived: sum of 2 quarters · filed 2025-02-27 | $10.59M derived: sum of 3 quarters · filed 2025-02-27 | $11.69M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.10M derived: sum of 2 quarters · filed 2025-02-27 | $7.21M derived: sum of 3 quarters · filed 2025-02-27 | $7.55M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $2.26M 10-Q · filed 2023-11-02 | $3.37M derived: sum of 2 quarters · filed 2023-11-02 | $3.71M 10-Q · filed 2023-11-02 | $3.78M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | $1.11M 10-Q · filed 2023-08-07 | $1.45M 10-Q · filed 2023-08-07 | $1.52M derived: sum of 3 quarters · filed 2024-03-11 | $1.58M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | $342.00K 10-Q · filed 2023-05-11 | $410.00K derived: sum of 2 quarters · filed 2024-03-11 | $474.00K derived: sum of 3 quarters · filed 2024-03-11 | $578.00K derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $132.00K derived: sum of 2 quarters · filed 2024-03-11 | $236.00K derived: sum of 3 quarters · filed 2024-03-11 | $431.00K 10-K · filed 2024-03-11 | ||
| 2021-09-30 | $64.00K 10-Q · filed 2022-11-08 | $168.00K derived: sum of 2 quarters · filed 2022-11-08 | $363.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $104.00K 10-Q · filed 2022-08-08 | $299.00K 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | $195.00K 10-Q · filed 2022-05-04 | |||||
| 2020-12-31 | $3.96M 10-K · filed 2023-03-01 | |||||
| 2019-12-31 | $10.98M 10-K · filed 2022-03-07 | |||||
| 2018-12-31 | $6.68M 10-K · filed 2021-02-25 | |||||
| 2017-12-31 | $1.62M 10-K · filed 2020-03-02 | |||||
| 2016-12-31 | $127.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |